The following criteria provide an overview of the types of studies considered by the journal:
Findings that have not been previously published in another tumor model.
Studies performed in multiple cell lines.
Conclusions that are not representative of incremental findings.
Studies that include a clearly written title and abstract that communicate the study's impact of significance to non-experts.
An incisive rationale that could interest a broad audience.
Manuscripts containing in vivo data. Although in vivo data is not required, studies containing this data are preferred.
A potentially generalizable, broad impact conclusion.
Studies that describe RNA interference (RNAi) must contain one non-specific control and two specific siRNAs for each knockdown target of interest. Additional data is required that demonstrates knockdown achievement at the level of protein expression (not just mRNA).